Liraglutide and Heart Failure in Type 2 Diabetes

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01425580
• Other study ID #: EU-nr 2010-022695-31
• Secondary ID: 2010-022695-31
• Status: Completed
• Phase: Phase 2
• First received: August 26, 2011
• Last updated: August 31, 2016
• Start date: January 2012
• Est. completion date: August 2016

Study information

• Verified date: August 2016
• Source: Karolinska Institutet
• Contact: n/a
• Is FDA regulated: No
• Health authority: Sweden: Medical Products Agency
• Study type: Interventional

Clinical Trial Summary

Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with insulinotropic properties. Apart from the glycemic actions, cardiovascular effects by GLP-1 have recently been reviewed. Receptors for GLP-1 are expressed in the rodent and human heart and acute activation of GLP-1 signalling has been shown to influence e.g. heart rate and blood pressure. In a knock-out mouse model, GLP-1R-/- mice exhibited a defective cardiovascular contractile response together with left ventricular hypertrophy. GLP-1 improves severe left ventricular heart failure in humans suffering from a myocardial infarction. Hence, it has been demonstrated that GLP-1 exerts direct functional effects through both GLP-1 receptor dependent and independent pathways in the heart.

Native GLP-1 is an extremely short acting peptide, with a half-time breakdown of 1-2 minutes, a feature that makes it unsuitable as a drug treatment for type 2 diabetes. To this end, several long-acting GLP-1 analogues, drugs for treating type 2 diabetes, have been tested for this purpose. The analogue liraglutide exerts its effects via the native GLP-1 receptor, localized not only on the pancreatic β-cells, but also in the human heart. Interestingly, liraglutide has been demonstrated to have beneficial effect on heart function in mice. Taken together, recent data shows that GLP-1 and its stable analogue liraglutide exert beneficial cardiovascular effects.

The purpose of this study is to determine whether the glucagon-like peptide-1 (GLP-1) analogue liraglutide improves heart function (measured as left ventricle longitudinal function and/or functional reserve during rest and/or after exercise) after 18 weeks of liraglutide + metformin, compared with glimepiride + metformin, using tissue Doppler echocardiography.

Description:

The subjects will attend a screening visit (Visit 1) in order to assess their eligibility. If found eligible, the subjects will return at Visit 2 within approximately 4 weeks, after Visit 1, with an up-titration with metformin 1 g BID or the maximal tolerated dosage of metformin (Run-in period).

At Visit 2 patients will be tested for;

• Heart function at rest and during an exercise ECG Stress Test with tissue Doppler echocardiography

• 24-hour blood pressure

• Anthropometric assessment

• Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).

• Quality of life (SF 36)

• Blood test (venipuncture)

Subsequently thereafter, subjects will during visit 2 be randomized to receive either liraglutide 1.8 mg s.c. (initial dose of 0.6 mg with an up-titration of 0.6 mg every week, final dose 1.8 mg QD) or glimepiride 4 mg p.o (initial dose of 2 mg, with an up-titration of 1 mg every week, final dose 4 mg QD).

At Visit 2, subjects will be supplied with a glucose meter (Abbot Contour) and instruction on use of the device including regular calibration according to the manufacturer's instruction. Subjects will be instructed on how to record the results of the self measured plasma glucose (SMPG) values in the meter. Subjects will then ask to monitor a 7 point profile glucose curve consecutively in three days before visit 3, at visit 4 and at the end of treatment (visit 5). SMBG values will be transferred via a computerized system (Diasend®).

Visit 3. Telephone visit. Self-reporting glucose measurements.

Visit 4. Telephone visit. Self-reporting glucose measurements.

At week 18 (Visit 5), subjects will be re-tested for:

• Heart function at rest and during an exercise ECG Stress Test with tissue Doppler echocardiography

• 24-hour blood pressure

• Anthropometric assessment

• Symptoms of dyspnea or fatigue (scoring system, classified as NYHA).

• Quality of life (SF 36)

• Blood test (venipuncture)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Type 2 diabetes.

2. Heart Failure, visualized with echocardiography, one of the following (2.1, 2.2 or 2.3).

• Ejection Fraction = 50%.

• Decreased systolic velocity (four chamber view) where two, out of four segments (Septum, Lateral, Inferior and Anterior Wall) has a relative decrease in velocity of 20% compared to a normal population.

• Evidence of diastolic dysfunction as shown by abnormal left ventricular relaxation, filling, diastolic distensibility or stiffness. An E/E' ratio (ratio of early diastolic velocities of mitral inflow derived Doppler imaging and myocardial movement derived by tissue Doppler imaging) >15 is considered diagnostic of diastolic dysfunction and an E/E' ratio < 8 as diagnostic of the absence of diastolic heart failure. An increased left atrial size (>49 ml/ m2) and an increased left ventricular mass (>122 g/m2 in women and >149 g/m2 in men) are considered sufficient evidence of diastolic dysfunction when the E/E' ratio is inconclusive.

3. HbA1c (accordingly to IFCC) 47 mmol/mol - 95 mmol/mol.

4. If antihypertensive treatment, the medication has to be stable, no change, for the last 1 month.

5. Male and female subjects, 18-80 years of age.

6. Signed informed consent form.

Exclusion Criteria:

1. Type 1 diabetes (autoantibody positive).

2. Any history of receiving GLP-1 analogues or dipeptidyl peptidase inhibitors (DPP-IV inhibitor) or glimeperide.

3. Previous treatment with glitazones within 6 months.

4. Previous treatment with other sulphonylurea within 3 months.

5. Previous treatment with insulin (any regimen) within 1 month.

6. Known severe heart failure, classified as NYHA 3-4.

7. Significant ischemic heart disease (defined as angina-limited exercise or unstable angina); documented acute myocardial infarction (MI) within the previous 8 weeks.

8. Active myocarditis; malfunctioning artificial heart valve.

9. Atria fibrillation or flutter

10. History of ventricular tachycardia within 3 months before study entry; second- or third-degree atrioventricular block.

11. Implanted pacemaker.

12. Supine systolic blood pressure <85 mm Hg or >200 mm Hg.

13. Primary renal impairment (creatinine clearance < 30 ml/min), or creatinine clearance < 60 ml/min if treated with metformin.

14. Uncorrected hypokalemia or hyperkalemia (potassium <3.5 mmol/l or >5.5 mmol/l).

15. Significant anemia (Hb < 90 g/l)

16. Treatment with another investigational agent within 30 days before study entry, judged by the investigator.

17. Severe gastrointestinal disease, including gastroparesis. As judged by the investigator.

18. Body mass index (BMI) > 40 kg/m2.

19. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Patients with intraepithelial squamous cell carcinoma of the skin treated with topical 5FU and subjects with basal cell skin cancer are allowed to enter the trial.

20. Females of child bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice).

21. Current drug and alcohol abuse.

22. History of acute or chronic pancreatitis

23. Subjects considered by the investigator to be unsuitable for the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Congestive Heart Failure
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Heart Failure
• Type 2 Diabetes Mellitus

Intervention

Drug:
• liraglutide
1.8 mg s.c. (QD)
• glimepiride
4 mg p.o. (QD)
• Metformin
500 mg p.o. (BID)

Locations

Country	Name	City	State
Sweden	Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset	Stockholm
Sweden	Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB	Stockholm

Sponsors (2)

Lead Sponsor	Collaborator
Thomas Nystrom	Örebro University, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography		18 weeks	No
Secondary	24-hour blood pressure		18 weeks	No
Secondary	Energy delivering from the carotid artery		18 weeks	No
Secondary	N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in serum over time and symptoms of dyspnea or fatigue as assessed by patient and clinician using established scoring systems		18 weeks	No
Secondary	Gene and protein expression (Affymetrix/proteomics)		18 weeks	No
Secondary	Plasma markers of inflammation i.e. hsCRP, IL-6, TNF-a and PAI-1		18 weeks	No
Secondary	Plasma markers of endothelial activation i.e. E-selectin, VCAM-1, ICAM-1 and plasma levels of nitrate/nitrite		18 weeks	No
Secondary	Lipids		18 weeks	No
Secondary	A1c		18 week	No
Secondary	Body weight		18 weeks	No
Secondary	Adverse events in terms of hypoglycaemia		18 weeks	Yes
Secondary	Quality of life (SF 36)		18 weeks	No
Secondary	Exercise ECG, including working capacity		18 weeks	No
Secondary	Global LV function (echocardiography) expressed as ejection fraction (EF)		18 weeks	No